We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Cronos Group (CRON - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Cronos Group is a member of our Medical group, which includes 947 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cronos Group is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CRON's full-year earnings has moved 87.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CRON has moved about 38.1% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 5.3% on a year-to-date basis. This means that Cronos Group is performing better than its sector in terms of year-to-date returns.
Castle Biosciences, Inc. (CSTL - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 42.7%.
For Castle Biosciences, Inc., the consensus EPS estimate for the current year has increased 48.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Cronos Group belongs to the Medical - Drugs industry, which includes 146 individual stocks and currently sits at #74 in the Zacks Industry Rank. Stocks in this group have gained about 6.4% so far this year, so CRON is performing better this group in terms of year-to-date returns.
On the other hand, Castle Biosciences, Inc. belongs to the Medical - Biomedical and Genetics industry. This 465-stock industry is currently ranked #88. The industry has moved +18.2% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Cronos Group and Castle Biosciences, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Cronos Group (CRON - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Cronos Group is a member of our Medical group, which includes 947 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cronos Group is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for CRON's full-year earnings has moved 87.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, CRON has moved about 38.1% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 5.3% on a year-to-date basis. This means that Cronos Group is performing better than its sector in terms of year-to-date returns.
Castle Biosciences, Inc. (CSTL - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 42.7%.
For Castle Biosciences, Inc., the consensus EPS estimate for the current year has increased 48.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Cronos Group belongs to the Medical - Drugs industry, which includes 146 individual stocks and currently sits at #74 in the Zacks Industry Rank. Stocks in this group have gained about 6.4% so far this year, so CRON is performing better this group in terms of year-to-date returns.
On the other hand, Castle Biosciences, Inc. belongs to the Medical - Biomedical and Genetics industry. This 465-stock industry is currently ranked #88. The industry has moved +18.2% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Cronos Group and Castle Biosciences, Inc. as they could maintain their solid performance.